- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Eprontia, Trokendi XR, Qudexy XR, Topamax
Synonyms :
Class :
Anticonvulsants; Antimigraine agents
Dosage forms & Strengths:
Adult:
Tablet:
25 mg
50 mg
100 mg
200 mg
Capsule:
15 mg
25 mg
Oral solution:
25 mg/ ml
CNS depressants increase the effect of flunarizine
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
CNS depressants increase the CNS suppression effect of thalidomide
loop Diuretics may enhance the hypokalemic effect of topiramate
loop Diuretics may enhance the hypokalemic effect of topiramate
loop Diuretics may enhance the hypokalemic effect of topiramate
CNS depressants increase the CNS depressing effect of brexanolone
it increases the effect of CNS depressants
topiramate increases the CNS depressing effect of carbamazepine
hyponatremic agents increase the effect of desmopressin
it increases the effect of CNS depressants
it increases the effect of CNS depressants
carbonic anhydrase inhibitors decrease the excretion of flecainide
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of sedation of metyrosine
it decreases the concentration of anti-seizure agents in serum
CNS depressants increase the effect of sedation of ropinirole
CNS depressants increase the effect of sedation of rotigotine
it increases the toxicity of CNS depressants
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
it increases the toxicity of metformin
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
anticholinergic agents increase the toxic or adverse effects of topiramate
anticholinergic agents increase the toxic or adverse effects of topiramate
anticholinergic agents increase the toxic or adverse effects of topiramate
anticholinergic agents increase the toxic or adverse effects of topiramate
anticholinergic agents increase the toxic or adverse effects of topiramate
when both drugs are combined, there may be an increased metabolism of erlotinib
both the drugs may enhance the risk of nephrotoxicity
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
anticholinergic agents increase the toxicity of topiramate
it increases the CNS depressing activity of perampanel
may diminish the serum concentration
may increase the toxic effects of anti-cholinergic
may increase the toxic effect of anticholinergic agents
may increase the toxic effect of anticholinergic agents
- may increase the toxic effect of antipsychotic agents
may increase the toxic effect of Antipsychotic Agents
may increase the adverse effect of Anticholinergic Agents
may diminish the excretion rate of each other when combined
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
topiramate decreases the concentration of hormonal contraceptives in the serum
topiramate decreases the concentration of hormonal contraceptives in the serum
topiramate decreases the concentration of hormonal contraceptives in the serum
topiramate decreases the concentration of hormonal contraceptives in the serum
it increases the effect of CNS depressants
it decreases the effect of anti-seizure agents
anti-seizure agents decrease the effect of metyrapone
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of zolpidem
it decreases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the concentration of hormonal contraceptives in serum
>10%:
Dizziness
Fatigue
Ataxia
Nervousness
Paresthesia
Psychomotor slowing
Abnormal vision
Anorexia
Confusion
Decreased memory
Nausea
Speech disorder
Injury
1-10%:
Abdominal pain
Weight loss
Diplopia
Mood problems
Pharyngitis
Tremor
Abnormal gait
Apathy
Asthenia
Dry mouth
Menorrhagia
Skin disorder
Taste change
Edema
Hypertension
Syncope
Bradycardia
Pallor
<1%:
Angina
Erythema
Hepatic failure
Hyperthermia
Hypokalemia
Neuropathy
Topiramate is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.
Pregnancy consideration:
Category C.
Breastfeeding warnings:
The effect during lactation is unknown
Pregnancy category:
Patient information leaflet
Generic Name: topiramate
Pronounced: to-pira-mate
Why do we use topiramate?
Topiramate treats migraine and lennox gastaut syndrome.